Oral Brain-Penetrant NLRP3 Inflammasome Inhibition (BGE-102) as Clinically-Ready Aging-Biology-Derived Pharmacology

NLRP3 inflammasome inhibitors are being developed as oral small molecules for inflammatory conditions; brain-penetrant candidates are in early clinical development, with efficacy in late-stage indications not yet established.

Type

evidence-claim

Domain

h11_chronic_inflammation

Grade

B

License

CC BY-NC 4.0

card_id

L-010

hallmarks

h11_chronic_inflammation

cluster

clinical_translation

primary_disease_area

longevity_general

evidence_tier

B

evidence_anchor_count

4

intake_round

R23

intake_date

2026-05-26

related_experts

related_biomarkers

related_interventions

bge_102_nlrp3

related_trials

collection_pages

/research/hallmarks/h11-chronic-inflammation,/research/interventions/nlrp3-inhibitors

LongProof Longevity Dynamic · LIGHT HOPE / x1000.ai · longevity.x1000.ai · 2026 · source

Read-only aggregated view. Longevity Evidence is the source of record; this catalog shows provenance as-is — no ratings, no reviews.